Abstract: In one aspect, compositions and therapeutic use thereof are provided that can inhibit ?-synuclein cell-to-cell transmission. In embodiment, methods are provided to treat a mammal such as a human that is suffering from or susceptible to an ?-synucleinopathy that include administering to the mammal an effective amount of one or more metal nanozymes.

Abstract: Disclosed are a [1,2,4]triazolo[1,5-a]pyridine compound as JAK inhibitor and an application thereof in preparing a drug for treating a disease related to JAK1 or/and TYK2. Specifically, the present invention relates to a compound represented by formula (I), or an isomer or pharmaceutically acceptable salt thereof.

Abstract: The present invention discloses the crystal forms as a JAK inhibitor and their application in the preparation of drugs for the treatment of JAK1 or/and TYK2 related diseases.

Abstract: Disclosed are a tri-heterocyclic compound as a JAK inhibitor, and the use thereof in the preparation of a drug for treating JAK1- or/and JAK2-related diseases. Specifically, the present invention relates to a compound as shown in formula (I?) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed in the present application are a class of compounds as JAK inhibitors and use thereof in the preparation of medicaments for treating JAK and TYK2 related diseases. Specifically, a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof is disclosed.

Abstract: Disclosed are a [1,2,4]triazolo[1,5-a]pyridine compound as JAK inhibitor and an application thereof in preparing a drug for treating a disease related to JAK or/and TYK2. Specifically, the present invention relates to a compound represented by formula (I), or an isomer or pharmaceutically acceptable salt thereof.

Abstract: Disclosed in the present application are a class of compounds as JAK inhibitors and use thereof in the preparation of medicaments for treating JAK and TYK2 related diseases. Specifically, a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof is disclosed.

Abstract: The present invention discloses crystal forms and salt forms of a 7H-pyrrolo[2,3-d]pyrimidine compounds and preparation methods thereof, and further discloses use of the crystal forms and the salt forms in the manufacture of a medicament for treating arthritis.

Abstract: The present invention discloses a series of JAK inhibitors, and particularly discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof and the use thereof in preparation of drugs for treating diseases related to JAK.

Abstract: The present invention discloses crystal forms and salt forms of a 7H-pyrrolo[2,3-d]pyrimidine compounds and preparation methods thereof, and further discloses use of the crystal forms and the salt forms in the manufacture of a medicament for treating arthritis.

Abstract: A compound having the structure of below Formula (I), or pharmaceutically acceptable salts thereof, are useful as JAK inhibitors, wherein R1, R2, L1, L2, T and X are as herein described.

Abstract: A compound having the structure of below Formula(I), or pharmaceutically acceptable salts thereof, are useful as Janus kinase inhibitors, wherein R1 and L1 are as herein described.

Abstract: Disclosed is a series of JAK inhibitors, which specifically relates to a compound shown in formula (I) or pharmaceutically acceptable salts thereof.

Abstract: Disclosed are a series of Janus kinase inhibitors, and particularly disclosed are a compound or pharmaceutically acceptable salts thereof of Formula (I) and use thereof in the preparation of drugs for treating Janus kinase (JAK)-related diseases.

Abstract: An apparatus for powering an electrical circuit includes a first voltage input configured to receive power from a first voltage source, a second voltage input configured to receive power from a second voltage source, wherein the second voltage source has a lower voltage than the first voltage source, a voltage regulator connected to the first voltage input, and a voltage output configured to switchably receive power from the first voltage input through the voltage regulator or from the second voltage input.

Abstract: The present invention discloses a series of JAK inhibitors, and particularly discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof and the use thereof in preparation of drugs for treating diseases related to JAK.

Abstract: An apparatus for powering an electrical circuit includes a first voltage input configured to receive power from a first voltage source, a second voltage input configured to receive power from a second voltage source, wherein the second voltage source has a lower voltage than the first voltage source, a voltage regulator connected to the first voltage input, and a voltage output configured to switchably receive power from the first voltage input through the voltage regulator or from the second voltage input.

Abstract: Described embodiments provide for, in a SerDes device, an adaptation process that adjusts data path gain through programmable-bias based on process, voltage, temperature (PVT) and data rate changes. Such adaptation process extends bias current dynamic range, and low frequency gain can be programmed to a desired target range of values for a given variable gain amplifier (VGA) setting at any PVT and data rate corner. A receive (RX) data path structure auto-adapts data path gain through programmable bias based on sensed PVT and data rate changes. The low frequency attenuation/gain range is extended, and can be programmed to a desirable targeted range by a SerDes device RX adaptive process for a given VGA and linear equalizer (LEQ) setting at any given PVT and data rate condition.

Abstract: Described embodiments provide for, in a SerDes device, an adaptation process that adjusts data path gain through programmable-bias based on process, voltage, temperature (PVT) and data rate changes. Such adaptation process extends bias current dynamic range, and low frequency gain can be programmed to a desired target range of values for a given variable gain amplifier (VGA) setting at any PVT and data rate corner. A receive (RX) data path structure auto-adapts data path gain through programmable bias based on sensed PVT and data rate changes. The low frequency attenuation/gain range is extended, and can be programmed to a desirable targeted range by a SerDes device RX adaptive process for a given VGA and linear equalizer (LEQ) setting at any given PVT and data rate condition.

Abstract: In described embodiments, process, voltage, temperature (PVT) compensation in a serializer/deserializer (SerDes) device employs a closed loop adaptation compensation that is incorporated into the SerDes receiver adaptation process. A detection method, where the adapted decision feedback equalizer (DFE) target level (e.g., tap H0) is monitored, employs this DFE target level when implementing a closed loop variable gain amplifier adaptation. The DFE target level in conjunction with the VGA level is used to control the PVT setting to maintain target SerDes data path gain by detecting aPVT corner condition. The detected PVT corner condition is employed to generate a control signal to further adjust the LEQ and DFE data path differential pair gain as required by the PVT condition.